Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed?

• Kodiak Sciences has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation, advancing a bispecific IL-6/VEGF therapy through a pivotal analysis that will inform regulatory paths.
• An interesting aspect of this update is how PEAK and the complementary PINNACLE study are structured to span a broad spectrum of MESI severity, from mild to more advanced disease, potentially broadening the therapy’s clinical relevance if results support its use.
• With these Phase 3 milestones in sight, we’ll examine how KSI-101’s bispecific IL-6 and VEGF mechanism reshapes Kodiak Sciences’ investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

What Is Kodiak Sciences' Investment Narrative?

For Kodiak Sciences, the big picture is whether you believe KSI-101 and the broader retina franchise can eventually justify a loss-making, high-valuation business that currently has less than a year of cash runway and no revenue. The completion of the first 300-patient PEAK cohort is important because it locks in a defined catalyst path, with the first pivotal readout now visible in December 2026 and a second in mid-2027. That helps frame the timeline for when the market might reassess both Kodiak’s science and its funding needs, but it does not remove the near-term financing risk flagged by the going concern warning and past dilution. With the share price already up very sharply over the past year, this update mostly reinforces, rather than transforms, the existing risk and catalyst profile.

But there is one funding-related risk here that investors should not overlook. Kodiak Sciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range from about US$65 to over US$400 per share, underscoring how far apart views on Kodiak’s potential sit. When you set that against the company’s continued losses and limited cash runway, it underlines why many readers may want to weigh several different perspectives before forming a view on the stock.

Explore 2 other fair value estimates on Kodiak Sciences - why the stock might be worth over 8x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Kodiak Sciences research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Kodiak Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kodiak Sciences' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com